This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
The United States now has a third coronavirus vaccine authorised for use. Johnson & Johnson (NYSE: JNJ)‘s vaccine, developed by its subsidiary Janssen, received Emergency Use Authorisation (EUA) from the FDA on Saturday. This followed a unanimous vote by the regulator’s vaccines and related biological products advisory committee that it do so.
In contrast to the two shots required for both of the other FDA-authorised coronavirus vaccines — Moderna Inc (NASDAQ: MRNA)‘s mRNA-1273 and Pfizer Inc (NYSE: PFE) and BioNTech (NASDAQ: BNTX)‘s BNT162b2 — Johnson & Johnson’s is a one-shot inoculation.
It also has relatively less burdensome storage requirements, as it can be kept for as long as three months in standard refrigeration temperatures of 36 to 46 degrees Fahrenheit.
The Johnson & Johnson vaccine demonstrated notably lower efficacy (72%) in late-stage testing compared the 95% or so of its two peers. However, 72% is still considered unusually high by vaccine development standards, plus Johnson & Johnson’s was shown to be 100% efficacious in preventing hospitalisation and death.
The Moderna and Pfizer/BioNTech shots were authorised in December and so far have been administered to nearly 15% of the US population. So it’s likely that Johnson & Johnson’s jab won’t lap past them, no matter its advantages. It will, however, help push the inoculation rate up quickly.
Investors should be aware that Johnson & Johnson won’t be making money from the vaccine during the pandemic. As it reiterated in the press release trumpeting the EUA, it will provide the jab “on a not-for-profit basis for emergency pandemic use.”
The company added that it has already started to ship the vaccine, with the goal of delivering enough to inoculate over 20 million people in the US by the end of March. 100 million doses should be shipped by the end of June.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
More reading
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Johnson & Johnson and Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post Johnson & Johnson coronavirus vaccine wins FDA authorisation appeared first on The Motley Fool Australia.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
from The Motley Fool Australia https://ift.tt/3dRrRjz
Leave a Reply